Drug Profile
ACT 901
Alternative Names: ACT-901; AFP-paclitaxel; Alpha-fetoprotein-paclitaxel conjugate; Third generation paclitaxel therapyLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Alpha Cancer Technologies
- Class Antineoplastics; Diterpenes; Drug conjugates; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Canada
- 28 Jul 2020 ACT 901 is still in preclinical development in Cancer in Canada
- 22 Jul 2020 Alpha Cancer Technologies in-licenses E. coli SoluPro® protein expression technology from AbSci licensed for the production of recombinant Human Alpha-fetoprotein